Clinical trial
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a…
NCT03041311 · G1 Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT03041311 |
|---|---|
| Title | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC |
| Official title | Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC) |
| Lead sponsor | G1 Therapeutics, Inc., Industry |
| Collaborators | Roche-Genentech Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Trilaciclib, Placebo, Carboplatin, Etoposide, Atezolizumab |
| Enrollment | 107 |
| Start date | Jun 29, 2017 |
| Primary completion | Aug 17, 2018 |
| Completion | Oct 29, 2020 |
| First posted | Feb 2, 2017 |
| Last update posted | Sep 25, 2025 |
| Countries | Bulgaria, Estonia, France, Latvia, Spain, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: